Abby Hardy, Author at BioTuesdays

Developments

Titan Pharma’s Probuphine now available at Crossroads of Southern Nevada rehabilitation facilities

Titan Pharmaceuticals (NASDAQ:TTNP) reported that Crossroads of Southern Nevada rehabilitation facility has trained health care providers in the insertion and removal of Probuphine implants, which will now be offered to...

October 1, 2019

Executive Moves

Sangamo Therapeutics names Dr. Bettina Cockroft as SVP and CMO

Bettina Cockroft Sangamo Therapeutics (NASDAQ:SGMO) appointed Dr. Bettina Cockroft as SVP and CMO to oversee clinical development activities and operations. Sangamo is using its ex vivo gene-edited cell...

September 30, 2019

Developments

Geron imetelstat gets FDA fast track designation for myelofibrosis

Geron’s (NASDAQ:GERN) imetelstat, a telomerase inhibitor, received FDA fast track designation for the treatment of relapsed/refractory myelofibrosis (MF). MF is a chronic blood cancer that impairs normal blood...

September 30, 2019

Markets

Stifel starts Fate Therapeutics at buy; PT $27

Stifel launched coverage of Fate Therapeutics (NASDAQ:FATE) with a “buy” rating and $27 price target. The stock closed at $15.47 on Sept. 28. Fate is using its induced pluripotent stem cell (iPSC) platform to develop...

September 30, 2019

Executive Moves

electroCore names Daniel Goldberger as CEO

Daniel Goldberger electroCore (NASDAQ:ECOR) has appointed Daniel Goldberger as CEO, effective Oct. 1. Mr. Goldberger has more than 35 years of experience in the biotechnology and medical technology industries; with...

September 30, 2019

Developments

AVEO Oncology begins enrollment for Phase 1b/2 study of FOTIVDA for HCC

AVEO Oncology (NASDAQ:AVEO) began enrolling patients for its Phase 1b/2 clinical trial evaluating FOTIVDA, in combination with AstraZeneca’s IMFINZI, in patients with hepatocellular carcinoma (HCC) who have not received...

September 30, 2019

Developments

FDA clears Turning Point Therapeutics’ IND for TPX-0046

The FDA cleared Turning Point Therapeutics’ (NASDAQ:TPTX) IND for TPX-0046, a dual RET and SRC tyrosine kinase inhibitor (TKI) being developed for the treatment of solid tumors. The company plans to initiate a first-in...

September 30, 2019

Developments

Zenabis to supply cannabis extracts for PAX Labs’ Era vaporizer pods

Zenabis Global (TSX:ZENA) has agreed to supply cannabis extracts for PAX Era pods, which are designed for use with PAX Labs’ Era vaporizer device. Under the accord, Zenabis will supply cannabis extracts in the form...

September 30, 2019

Developments

Cheryl Reicin, renowned Canadian corporate lawyer, recognized at LMG Life Sciences awards

Cheryl Reicin, partner at Torys, was named Canada’s financial and corporate attorney of the year at the seventh annual LMG Life Sciences awards. Ms. Reicin is the practice leader of Torys’ life science group...

September 27, 2019

Developments

Cortexyme begins European screening for Phase 2/3 Alzheimer’s disease trial

Cortexyme (NASDAQ:CRTX) began screening patients in Europe for its international Phase 2/3 trial, called GAIN, to evaluate COR388 in patients with mild-to-moderate Alzheimer’s disease (AD). The company has been...

September 26, 2019

Author - Abby Hardy

Titan Pharma’s Probuphine now available at Crossroads of Southern Nevada rehabilitation facilities

Sangamo Therapeutics names Dr. Bettina Cockroft as SVP and CMO

Geron imetelstat gets FDA fast track designation for myelofibrosis

Stifel starts Fate Therapeutics at buy; PT $27

electroCore names Daniel Goldberger as CEO

AVEO Oncology begins enrollment for Phase 1b/2 study of FOTIVDA for HCC

FDA clears Turning Point Therapeutics’ IND for TPX-0046

Zenabis to supply cannabis extracts for PAX Labs’ Era vaporizer pods

Cheryl Reicin, renowned Canadian corporate lawyer, recognized at LMG Life Sciences awards

Cortexyme begins European screening for Phase 2/3 Alzheimer’s disease trial

Subscribe